

Index

a

- absorbents, partitioning of 334
- absorption
 - of nanoparticulates 335
 - and polarity (hydrophilicity/lipophilicity) 335
- AC. *see* articular cartilage (AC)
- accelerated blood clearance (ABC phenomenon) 107, 132
 - essentials and background 107
 - immunogenicity of PEG-conjugated nanomedicines 107, 108
 - PEG immunogenicity, mechanism of 108
- adapalene-loaded poly(lactic-co-glycolic) acid particles 340
- adenosine triphosphate (ATP) 367
 - ATP-competitive inhibition 371
 - ATP-site-dependent competition binding assays 370, 372
- adipose tissue derived stem cell (ASC) 309
- adverse immune effects of nanomedicines, experimental analysis of 110
 - measurement of C activation 110
 - prediction of CARPA 111–113
 - prediction of immunogenicity 110
- adverse immune effects of nanoparticles 98
- AFM. *see* atomic force microscopy (AFM)
- age-related neurodegenerative disease 11
- aging 5
- all-trans-retinoic acid 333
- Alzheimer's disease 16
- 5-aminolevulinic acid 342
- amorphous calcium phosphate (ACP) 279
- anaphylatoxins 99
- angiogenesis 128
- angioplasty 66
- aniline phenyl ring, 6-position of 368
- anionic nanoparticles (NPs) 56
- anisotropy 5, 17, 252
- ankylosing spondylitis 3
- anodic alumina oxidation (AAO) 303
- anodic porous alumina 308
- antibacterial effect 337
- antibody-dependent cellular cytotoxicity (ADCC) 140
- antibody nanoparticles 332
- anticancer drug discovery 365
- anticoagulation 90
- antidrug antibodies, immunogenicity and formation of 106, 107
- antidrug antibody (ADA) formation 98
- antigen–MHC complex 86
- antigen presenting cells (APCs) 99, 338
- antiseptis 336
- antithymoglobulin (ATG) 91
- arterial balloon dilatation 4
- articular cartilage (AC)
 - of human femoral head 254
 - mechanical function of 218
- artificial hips 5
- artificial macrostructures 17
- artificial muscles 325
- artificial nanophases 17
- artificial nanostructures 11
- atherosclerosis 53, 54, 56, 59, 60
 - formation 55
- atomic force microscopy (AFM) 209
 - basic operating principles 211, 212
 - in cell and tissue biology 211, 215
 - nanomechanical characterization of human tissues 225
 - surface properties and quality control of isolated tissue specimens 217
 - for tissue measurement 215, 216
- autoantigens 87

b

B cells 99
 BCR-Abelson (BCR-Abl) protein 368
 BCR-Abl phosphorylation 369, 370
 BCR-Abl protein 370
 – Gleevec blocked proliferation 368
 Bekhterev's disease 3
 benefit–risk perception 344
 Bevacizumab 227
 bicarbonate-buffered environment 196
 biodistribution, of nanoparticles 22
 biointeractions 16
 biological environment 17
 biological matter 4
 biological surfaces principles 271
 biomacromolecules 12
 biomarkers 31
 biophysical perspective 129
 biosensors 21
 bleeding patients 90
 blood circulation 339
 bone augmentation 22
 bone tissue regeneration 34, 35
 bottom-up technology 301–303
 Bovine spondylitis encephalopathy crisis 345
 Bragg equation 245
 brain tissue 256
 – myelin-related signal 258
 – SAXS-CT data 257, 258
 – two- and three-dimensional SAXS data 258
 – two-dimensional SAXS measurements 257, 258
 breast tumor 256
 – spatially resolved SAXS data 256

c

cancer drug discovery 367
 cancer therapy products 343
 capillary-like channels 204
 carbon nanotubes 35, 36, 64
 5(6)-carboxyfluorescein from selected vesicles 78
 cardiology 53, 56
 cardiomyocyte function 64
 cardiovascular diseases (CVDs) 3, 53
 – nanoparticles for treatment of 58
 cardiovascular repair 22
 caries 4
 CARPA. *see* complement (C) activation-related pseudoallergy (CARPA)
 CARPAgenic potential of nanomedicines 113

– decision tree to guide the evaluation 113
 carrier nanoparticles, for dealing with 13
 casein phosphopeptide (CPP) 279
 CCs. *see* corneocytes (CCs)
 CD4+ T cells 91, 92
 cell-based nanostructured scaffolds 33
 cell–cell interactions 191, 224, 229
 cell–ECM interactions 229
 cell growth, and differentiation 297
 cell growth, *in vitro* testing 368
 cell labeling/tracking 332
 cell–matrix interactions 191
 cell membrane 22
 cell receptors 12
 cellular adhesion complexes 300
 cellular infiltration 316
 cellular protein structures 315
 ceramics 21
 channel-like structures 334
 chemical vapor deposition (CVD) 53, 54, 58, 271, 273, 326
 chemotherapeutics in oncology 56
 chitosan 35
 – scaffold 35
 chlorhexidin 336
 – loaded nanoparticles 337
 chondrocytes 218
 chromosomal translocation 368
 chronic myeloid leukemia (CML) 367
 ciclosporin, in alopecia 341
 circulating biomarkers 13
 clinical applications 172
 – ependymoma 176, 177
 – skull-base chordomas 174–176
 – uveal melanoma 172–174
 clinically approved nanoproducts 37–39
 collagen-I 252
 colloidal lithography 300
 complement activation-related pseudoallergy 101
 – historic leads 101, 102
 – foundation of the concept 104
 – map of clinically relevant nanotoxicities 102
 – mechanism 105, 106
 – milestones in progress 105
 – prevalence, symptoms, and features 104
 – symptoms 103
 – tetrad 113
 complement systems 90
 composites 4, 271, 276, 277
 computed tomography (CT) 243
 congenital risk factors 321

- consecutive resurgeries 5
contaminating signal 127
corneocytes (CCs) 334
corpus cavernosum recti 322
cosmetic applications 335
cosmetic products notification portal (CPNP) 344
cosmetics, preventive care products 338
CPP-ACP nanocomplexes 279
cryo-TEM image, of Pad-PC-Pad vesicles 79
crystalline periods 303
cSAXS beamline 247
curcumin 342
CVD. *see* chemical vapor deposition (CVD)
CVDs. *see* cardiovascular diseases (CVDs)
cyclodextrin-containing cationic polymers (CDP s) 141
cystoscopy 318
cytocompatibility 5
- d**
- daily adapted proton therapy (DAPT) 181
Dalton rule 334
3D cell assemblies 203
2D cell culture in microfluidics 200
3D culture systems 194
decision tree, to guide evaluation of CARPAgenic potential 113
degenerative conditions 18
degenerative disorders 11
dementia 11
dental implants 5, 15
dental stem cells, and regenerative potential 265–267
– dental pulp stem cells (DPSCs) 265
– human dental epithelial stem cells (hDESCs) 267
– induced pluripotent stem cells (iPSCs) 267
– periodontal ligament stem cells (PDLSCs) 267
– stem cells from human exfoliated deciduous teeth (SHEDs) 266
– stem cells from the apical part of the dental papilla (SCAPs) 266
– stem cells from the dental follicle (DFSCS) 267
dental tissues, repair of 264, 265
dentin 4
– scattering curves of 253
dental collagen network 4
dentin–enamel junction (DEJ) 252
dentin hypersensitivity 278
– and enamel remineralization
– – nanoscale modification in treatment of 278, 279
dermal dendritic cells 338
diagnostic nanosystems 21
diagnostics 31–33
1,3-diamidophospholipid 77
diazo compounds 75
dielectric elastomer 325
dielectric elastomer actuators 325
– for sphincter replacement 324–327
dielectric elastomer actuators (DEA) 5, 324
– operating principle 325
dielectric properties 13
dioleoyl phosphatidylethanolamine (DOPE) 142
1,2-dioleoyl-trimethylammonium-propane (DOTAP) 142
1,2-dipalmitoyl-sn-glycero-3-phosphocholine 72
directed self-assembly (DSA) 300
disease management 14
disease targets, high precision aim for 10, 11
DNA alkylation 366
DNA damages 380
DNA-damaging reactive oxygen species 337
DNA sequencing, cost 364
DNA tetrahedrons 365
Doxil 373
doxorubicin 143
DPPC vesicles 78
drug delivery 22, 23, 71
– multifunctional gold nanoparticles 343
– systems 97, 299
– transport obstacles encountered upon 23
drug-loaded nanoparticles 341
- e**
- ectosome 86
efflux pumps 22
electron beam lithography 31, 302
electron density 245
– distribution 246
electroporation 13
electrospinning 320
electrospun polylactic acid 35
elevated blood pressure 129
ellipsoidal vesicle 76
enamel 4
endoanal ultrasound (EUS) 323
endogenous proteins 21
endothelial cells 87

- endothelial nitric oxide synthase (eNOS)
 - 64
 - enhanced permeability 128
 - and retention (EPR) effect 127, 128
- epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) 128
- epigallocatechin gallate 36
- epirubicin 143
- epithelial-to mesenchymal transition (EMT) 227
- erythrocyte NVs (RBC-NVs) 84
- erythrocytes 87
- Escherichia coli* 342
- exosomes 86
- external anal sphincter muscle (EAS) 321
 - rectoanal excitatory reflex (RAER) 322
- extracellular chaperone 17
- extracellular matrix (ECM) 319
 - proteins 209
- extracellular vesicle (EV) 85
 - biology 86, 87
- f**
- fabricated macroporous PLGA microspheres 324
- fecal incontinence 321
 - dielectric elastomer actuators for sphincter replacement 324–327
 - etiology 321
 - fecal continence, physics of 321, 322
 - fecal in-/continence assessment 322, 323
 - tissue engineering for sphincter regeneration 323, 324
- fecal incontinence (FI) 321
 - risk factors 321
- femoral head 254–256
 - scanning SAXS measurement 255
 - spatially resolved SAXS data 255
 - two-dimensional position-resolved SAXS 254
- fibrin monomers 324
- fibrous proteins 16
- flexosome 330
- fluidic channels 305
- fluorescence microscopy 192
- folic acid
 - receptor-targeted NPs as contrast agents 137, 138
 - receptor-targeted NPs for drug delivery 136, 137
- Förster resonance energy transfer 363
- foster cell growth 296
- functional electrical stimulation (FES) 14
- g**
- gastrointestinal (GI) tract 315
- general inflammatory disease 54
- gene therapy 12
- genistein 342
- glaucoma 14
- glioblastoma tumors 129, 142
- glucocorticoids 341
- glutathione 75
- glycerol-phospholipid 72
- glycogen phosphorylase 367
- glycosaminoglycan 230
- gold nanoparticles 33, 65, 339, 342
- graft *versus* host disease (GvHD) 91
- green fluorescent protein (GFP) 363
- h**
- hair disorders 340
- hair follicles 339
 - infundibulum of 338, 340
- hair, gene therapy of 341
- hapten–protein complexes, in epidermis 336
- heart attack 53, 59
- hemoglobin 12
- HIF-1 α expression 195
- Hirschsprung's disease 321
- human chorionic gonadotrophin (hCG) 363
- human epidermal growth factor receptor 2 (HER2) 33
- human kinome 367–369
- human stratum corneum
 - sketch of morphology 334
- human umbilical vein endothelial cell (HUVEC) 309
- Hunter–Schreger bands 252
- hydrogel 59
- hydrophobic properties 301
- hydroxyapatite 35
 - crystallites 4
- hyperthermia 65
- hypoxia 53, 144, 195, 227
- hypoxia-induced changes 195
- hypoxia-inducible transcription factor 1 (HIF-1) 195
- hypoxic stress 14
- i**
- idiopathic thrombocytopenic purpura (ITP) 91
- immune stimulatory vicious cycle (ISVC) 97–100
- immunoglobulin G (IgG) 33
- immunoliposomes 142, 143
- immunomodulatory agents 341

- immunosensors 363
- immunotherapeutic approaches 342, 343
- inducible NOS (iNOS) lipoplexes 64
- infectious bacterial diseases 4
- infectious diseases 11
- inflammatory functions 83
- injection molding, molding tools 306
- inkjet bioprinting of cells 37
- $\alpha 5$ and $\alpha 2$ integrins 195
- intelligent functional electrical stimulation (FES) 14
- intercellular adhesion molecule (ICAM-1) 60
- intercellular communication 83
- intercellular space (IS) 334
- interleukin (IL)-13-dependent cell line 32D 368
- internal cell components 22
- internal medicine 10
- interstitial fluid pressure (IFP) 129
- in vivo* nanodiagnostics 13
- iron oxide nanoparticles 64
- isotropic polymers 4

- k**
- knees 5
- kojic acid 64

- l**
- laminin 37
- LCP. *see* liquid crystal polymer (LCP)
- leak-point pressure (LPP) 320
- lepirudin 90
- leukocytes 87
- light reflectance control 337
- lipid-based liquid crystalline nanoparticles 363
- lipid-based vehicles 337
- lipid peroxidation 337
- liposome-encapsulated hemoglobin (LEH) 102
- liposomes 21, 55, 59, 129, 142, 330, 373
 - based drug carriers 342
 - formulations 345
 - general characteristics 72–74
 - magnetic 13
 - membrane 77
 - release of vesicle-entrapped molecules 74
 - – enzymes as trigger 75
 - – pH changes as trigger 75
 - – photoreactions as trigger 75, 76
 - – redox reactions as trigger 75
 - – shear stress as trigger 76
 - – temperature as trigger 74
 - – ultrasound as trigger 75
 - self-assembled from double-tail phospholipids 73
- liquid crystal polymer (LCP) 308
- localized delivery of nanoparticles, strategies for 23
 - biomaterials 25, 26
 - external activation 26, 27
 - molecular targeting 26
 - physical targeting 24, 25
- Lotus-effect 298
- lymphangiogenesis 129
- lymphocytes 343

- m**
- magnetic iron oxide nanoparticles 64
- magnetic nanoparticles 65
 - of iron derivatives 342
- magnetic resonance imaging (MRI) 318
- malignant neoplasms 380
- mechanical stress 55
- mechanobiological properties 209
- mechanosensitive drug delivery systems 65
- melanoma 87
- metabolic pathways/signaling 379
- metabolites 83
- metallic load-bearing implants 5
- metal oxide-based nanoparticles 15
- metastatic melanoma 332
- microcantilevers 303
- microcavity 305
- microfluidic cell culture 197
 - expanding, to third dimension 200–204
- microfluidic device 192
 - assembly and disassembly of actin networks 193
 - for 3D cell growth 202
- microfluidics 191
 - biomimetic models, of cancer 204
 - chips 192
 - device (*see* microfluidic device)
 - platforms 194
 - structures, specialized in 193
- microinjection molding 304
- micro- or nanovesicles (NVs) 83
- micro-RNA 83
- molded polymer, SEM micrographs 307
- molecular beam deposition (MBD) 326
- monosodium urate (MSU) crystals 89
- Monte Carlo simulations 185
- MR-defecography 323
- MSC cells 299

- multicellular Rat2 and Rat2-sm9 spheroids 201
- multicomponent protein patterning 300
- multidrug resistance (MDR) phenotype 128
- multifunctional contrast agents 14
- multiplexed volumetric bar-chart chip (V-Chip) 32
- multistage propelled V-Chip (MV-Chip) 32
- musculoskeletal system 5
- Mycobacterium tuberculosis* (MTB) antigens 32
- n**
- nanoanatomy 9
 - of human hard and soft tissues 251
 - brain tissue 256–258
 - breast tumor 256
 - femoral head 254–256
 - human tooth 251–254
- nanoarchitectures 17
- nano-based diagnostic tests 39
 - approved by the FDA 39
- nanobeams 15
- nanobiology 16
- nanobots 16
- nanocardiology 56
 - drug delivery systems 56
- nanocarrier 13
- nanocomponents 14
- nanodiagnosics 33
- nanoendoscopy 14
- nanofabrication technologies 293
- nanofibers 301
- nanofillers, in dental restorative materials 276, 277
- nanohydroxyapatite 35
- nanointerfaces 21
- nanolayers, usable for masking or protection 12
- nanomaterials 16
 - interacting with specific intracellular signals 13
 - for medical applications 55
- nanomechanical characterization
 - of human tissues by AFM 225
- nanomechanical signature, of articular cartilage 217
 - articular cartilage composition and function 217–219
 - nanomechanics of articular cartilage 219–221
- nanomechanical signature, of mammary tissues 223
 - correlating nanomechanical response with tumor progression and 228
 - mammary gland composition, and mechanics 223, 224
 - nanomechanical signature of breast cancer 224–229
- nanomechanical signature, of osteoarthritis 221
- nanomedical applications 83
- nanomedicine 16, 21, 66, 97, 329
 - application of 365–367
 - cabinet of 361–365
 - development, decisional analysis in 57, 58
 - global market 360, 361
 - kinase inhibitors, evolution of 370–372
 - molecular medicine to understand molecular basis of disease 361
 - nanoparticle delivery 372–374
 - origins of 359, 360
 - particle features influencing immune side effects of 109, 110
 - transition from discovery to clinical development 369, 370
- nanometer-size minerals 5
- nanometer-thin dielectric elastomer layers 380
- nanomodifications of bone replacements materials 275, 276
- nanoneuroprostheses 14
- nanoparticles (NPs) 21, 55, 128. *see also* protein-targeted NPs
 - containing stents 65
 - delivery platforms 373
 - in drug-eluting stents 63, 64
 - endogenous to atherosclerosis pathology 62
 - solutions 343
 - for treatment of CVD 58
- nanopattern
 - on flexible surfaces 299
 - to improve stent integration 64
- nanopillar-based foil
 - nondestructive fabrication of 305
- nanopillar cell culture plate 296
- nanopore 364
 - fabricated through a variety of techniques 31
 - self-ordering 303
- nanoporous liquid membranes 14
- nanoporous membrane structures 14
- nanoproduct 21
 - clinically approved 37–39
- nanopyramids 5

- nanorobots 12
- nanoscale
 - delivery systems 373
 - devices 12
 - materials 316
 - ordered topography 55
 - substitutes 10
 - surface modification approaches 279
- nanoscale surface modifications, of dental biomaterials 270
- approaches for nanoscale surface modification in dental implants 270, 271
- nanoscience, benefits 379–381
- nanoshells 364
- nanosilver, odor-reducing properties of 338
- nanosized vesicles 84
- nanosize topographies 301
- nanostructured dental implants, clinical applications of 273–275
- nanostructured lipid carriers 331
- nanostructured materials 329. *see also* nanoparticles (NPs); nanostructured polymers
- nanostructured polymers 299
 - applications of 295, 296
 - bioanalytic devices and medical implants 294
 - in biomedical applications 293, 294
 - – cell proliferation/differentiation 298–300
 - – combined effects 298
 - – Gecko-inspired bandage 301
 - – mimicking nature 300, 301
 - – nanoeffects 296–298
 - – protein nanopattern 300
 - bottom-up manufacturing by self-organization/surface postprocessing 303
 - cell response, to surface patterning 308, 309
 - generation processes of nanotopographies 301
 - microcantilevers using mold inlays 303–306
 - plasma etching 306–308
 - surface nanotopographies 294, 295
 - top-down processes 302, 303
- nanostructured surfaces, cellular responses to 272, 273
- nanotechnology 3, 14
 - applied to medicine 55
 - based approaches 55
 - based drug release agents 17
 - based innovations 4
 - based interventions 316
 - based tools 12
 - benefits 379–381
 - in dentistry (*see* nanotechnology in dentistry)
 - in medicine 39 (*see also* nanomedicine)
 - to patient treatment, awareness of risks introducing 57
- nanotechnology in dentistry 269
 - artificial stem cell niches, nanofiber scaffolds 270
 - gene, protein, and drug intracellular delivery 270
 - tracking stem cells, after transplantation 269, 270
- nanotherapeutics in surgical interventions 62
- nanotopographies, on surfaces 293
- nanotopography 300
- nanotoxicology 57
- nanotraps 31
 - fractionation and digestion of proteins in, schematic representation of 32
- nanovectors 127
- nanovesicles (NVs)
 - biophysical properties of 84
 - erythrocyte 89–91
 - – transfusion, triggers sequential activation of 90
 - neutrophil 89
 - platelet 91, 92
 - polymorphonuclear leukocytes 88, 89
- nature, of nanoparticles. *see also* nanomedicine; nanoparticles (NPs)
 - absorption pathways 333–335
 - antisepsis, prevention 336, 337
 - cancer 341–343
 - diagnosis/monitoring 338, 339
 - formulations, with nanoparticles 333
 - hair disorders 340, 341
 - inflammatory disorders 341
 - light reflectance control 337, 338
 - nanoparticles in topicals 344, 345
 - nature of nanoparticles 330
 - odor neutralizers 338
 - overview of 329, 330
 - photoprotection, color 337, 338
 - preventive care 338
 - regulatory issues 344
 - rigid particles 331, 332
 - risk/safety considerations 335, 336
 - sebaceous gland disorders 340
 - soft particles 330, 331
 - surface functionalization 332
 - surgery 343
 - vaccines 338
- neocartilage formation 22

- nerve growth factor (NGF) 320
 - nerve regeneration 36, 37
 - neural tissue engineering 37
 - neurodegenerative diseases 16, 381
 - neurointervention 11
 - neurological disorders 315
 - neutrophil NVs (PMN-NVs) 84
 - next-generation drug delivery vehicles 27
 - amplified drug delivery 29
 - biomimicry 29, 30
 - implantable devices 30, 31
 - sequential drug delivery 27–29
 - NIL fabricated hybrid mold 305
 - NIL toolbox approach 305
 - NIR laser 65
 - nitric oxide (NO) 58
 - nitroglycerin 3, 59
 - nitroprusside 59
 - noninvasive nature 14
 - normal human sera (NHS) 113
 - NP passive properties, physicochemical factors
 - influencing 129
 - density of ligands 134
 - electric charge 133, 134
 - size of the NP 130, 131
 - surface modification and opsonization 131–133
 - NPs. *see* nanoparticles (NPs)
 - nucleic acid-based nanomedicines 364
 - NVs. *see* nanovesicles (NVs)
- O**
- on-chip technology 192
 - opsonization 131–133
 - orthopedics 10
 - osteoblast adhesion 15
 - osteoblastic markers 35
 - osteocalcin (OCN) 299
 - osteogenic differentiation 35
 - osteopontin (OPN) 299
 - osteoporotic fracture 10
 - outer membrane vesicles (OMVs) 86
 - oxidative stress 15, 64
 - oxygen plasma
 - with a polymer surface 307
 - treated PEEK substrate 309
- P**
- paclitaxel (PTX) 137
 - pancreatic islet cell transplants 22
 - particle aggregation 333
 - particle membrane interactions 17
 - particle residence times 15
 - PEGylated 373
 - nanoparticles 109
 - PEGylated liposomal doxorubicin (Doxil[®]/Caelyx[®]) 143
 - loaded with doxorubicin 143
 - PEGylation 133, 134, 332
 - pelvic ultrasound 318
 - peptide nucleic acids (PNA) 362
 - perfluorocarbon gas 59
 - perfluorocarbon nanoparticles 60
 - peripheral nervous system 14
 - permeability enhancement 128
 - personalized medicine 22
 - P-glycoprotein 128
 - phagocytosis 17
 - pharmacodynamics 13
 - pharma-technological innovations 342
 - 2-phenylaminopyrimidine backbone
 - development of Gleevec 369
 - phospholipase A2 (PLA2) 75
 - phospholipids 72
 - pH-responsive chitosan 196
 - PILATUS single photon counting detector 247
 - pilosebaceous 341
 - plasma-treated electrospun poly(L-lactic acid)-co-poly(epsilon-caprolactone)/gelatin nanofibrous scaffolds 36
 - plasma-treated polymer films 308
 - plasma treatment 295, 307
 - plasmonic effects 305
 - plasmonic photothermal therapy (PPTT) 65
 - plasmon–plasmon resonance imaging 33
 - platelets 87
 - poly(amidoamine) dendrimers 331
 - polydimethylsiloxane (PDMS) 299, 326
 - nanometer-thin PDMS films 326
 - polyetheretherketone (PEEK) 293
 - plasma-treated PEEK films 309
 - polyetherketoneketone (PEKK) 293
 - polyethyleneimine 133
 - poly glycolic acid (PGA) 320
 - poly lactic acid (PLA) 35, 293, 319
 - poly(lactic-co-glycolic acid) (PLGA) 293
 - based nanoparticles, for gene delivery 59, 60
 - nanoparticles 63
 - poly(lactide-co-glycolide) nanoparticles 374
 - polymer-based hemostatic agents 343
 - polymer demixing 300
 - polymer films, SEM images of 308
 - polymeric drug-eluting stents (DESs) 63
 - polymeric micelles 21
 - polymeric nanoparticles 373
 - polymerization reactions 343

- polymer materials, by molding 294
 - polymersomes 55
 - polymorphonuclear(PMN) leukocytes 87
 - polyoxymethylene (POM) 308
 - porosity 34
 - porous silk fibroin 35
 - preventive care products 338
 - protein nanopattern 300
 - protein phosphorylation 367
 - protein-targeted NPs 141
 - targeting the epithelial growth factor receptor 143
 - targeting transferrin receptor 141, 142
 - proteoglycans (PG) 218, 221
 - proton physics 161
 - density heterogeneities 163, 164
 - energy loss 161
 - generating high-energy proton beams 164
 - – cyclotron 164, 165
 - – synchrotrons 165
 - linear energy transfer and relative biological effectiveness 163
 - multiple Coulomb scattering 161, 162
 - nuclear interactions and secondary particles 162
 - protons 4. *see also* proton physics; proton therapy
 - proton therapy, delivering 165
 - imaging and treatment planning 165, 166
 - passive scattering 166
 - – collimators 168
 - – compensators 168
 - – passive scattering in practice 168, 169
 - – single and double scattering 167, 168
 - – spread-out Bragg peak 166, 167
 - pencil beam scanning 169
 - – PBS vs. passive scattering 170, 171
 - – principle 169, 170
 - treatment gantries 171, 172
 - proton therapy, future of 177
 - clinical future of 182, 183
 - current and future technological developments 178
 - – in-room/onboard 3D imaging and adaptive therapy 180–182
 - – treatment delivery 178, 179
 - – treatment efficiency 179, 180
 - PBS 177, 178
 - role for nanotechnology 183
 - – dose enhancement 184, 185
 - – nanodosimetry 185, 186
 - – tumor imaging 184
 - pseudoallergy 100
 - pseudoviruses 100
 - psychological disorders 315
 - pulmonary arterial pressure (PAP) 112
- q**
- quantum dots 15, 331, 339, 343
 - quantum tunneling 362
 - quasi-exclusive mode, of protection 337
 - quercetin 342
- r**
- radiation treatments 4. *see also* radiotherapy
 - radiotherapy 18
 - principles of 157
 - using protons 159, 160
 - with x-rays 157–159
 - Raman scattering 339
 - rectoanal excitatory reflex (RAER) 322
 - rectoanal inhibitory reflex (RAIR) 322
 - regenerative dentistry 267–269
 - enamel regeneration 268
 - periodontal tissue regeneration 268
 - pulp-dentin regeneration 268
 - root regeneration 268
 - whole-tooth regeneration 269
 - regenerative medicine 22, 33, 34
 - remineralization 380
 - replication processes, for surface patterning 302
 - retention effect 128
 - reticulocytes 86
 - reticuloendothelial system (RES) 17, 129
 - RGD-targeted gold NPs 139, 140
 - rigid nanoparticles 331
 - risk–benefit analysis 56
 - RNA degradation 217
 - robotics, for microrepair and healing 12
 - RondelTM technology 142
- s**
- sacrificial layer deposition 31
 - SAXS. *see* small-angle X-ray scattering (SAXS)
 - scanning electron micrograph
 - of synthetic biomimetic carbonate hydroxyapatite (CHA) nanocrystals 278
 - scanning electron microscopy 62
 - scattering angle 245, 246
 - scattering pattern analysis 249, 250
 - Scientific Committee on Consumer Safety (SCCS) 344
 - Scott syndrome 91
 - sebaceous gland 330

- secreted protein acidic and rich in cysteine (SPARC) 134
 - self-assembly processes 302, 331
 - self-cleaning property 298
 - self-confined plasma etching 303
 - self-organization mechanisms 302
 - self-regulated loading of cells, into microchambers 197–199
 - shear force-responsive vesicles 77–79
 - shear forces on vesicles, influence of 76, 77
 - shear-sensitive liposomes 379
 - single-photon emission computer tomography (SPECT) 184
 - single-walled carbon nanotube polymeric film 37
 - skin cancer 341
 - skin, feature of 339
 - skin malignancies 342
 - skin regeneration 35, 36
 - slings placement 320
 - small-angle X-ray scattering (SAXS) 244, 246–248, 253, 254, 258
 - brain tissue 256–258
 - breast tumor 256
 - femoral head 254–256
 - SAXS data processing 252
 - signal 253
 - small intestinal submucosa (SIS) 319
 - soft-lithography techniques 300
 - solid lipid nanoparticles (SLNs) 109, 331, 340
 - solubility 128
 - spatially resolved hard X-ray scattering 244
 - scattering pattern analysis 249, 250
 - tissue preparation 250, 251
 - two-dimensional scanning small-angle X-ray scattering 248
 - x-ray scattering 244–246
 - – experimental setup 246–248
 - spatiotemporal control
 - of cellular growth and organization 194
 - efficiency of 192
 - SPECT. *see* single-photon emission computer tomography (SPECT)
 - sphincter abnormalities 315
 - sphincter function 323
 - sphincter regeneration
 - tissue engineering for 323, 324
 - standard scattering measurement setup 253
 - Staphylococcus aureus* 337
 - stealth materials, for a more potent delivery 13
 - stenosis 54, 59, 78
 - stent implantation 54
 - stents 65
 - sterilization 294
 - stiffness 34
 - stratum corneum (SC) 330
 - stress urinary incontinence (SUI) 315
 - structure–function relationships 10
 - sunscreen products 337
 - superparamagnetic particles 14
 - surface chemistry 57
 - surface nanostructuring, functionalization 297
 - surface nanotopography 298
 - surface topographies 298
 - surface-to-volume ratio 336
 - synthetic nanochannels 31
 - synthetic polymeric scaffolds 319
- t**
- targeted drug discovery 367–369
 - targeted NPs 134, 135. *see also* nanoparticles (NPs)
 - targeting folate receptor, using folic acid as small ligand 135, 136
 - targeting integrin with peptides 138, 139
 - targeting vessel geometry 60, 61
 - target receptor, choice of 135
 - T7 bacteriophage 372
 - T cells 86, 99
 - TE. *see* tissue engineering (TE)
 - TfR-mediated transcytosis 142
 - theranostics 331
 - therapeutic agents 18
 - therapeutic carriers, to deliver antibiotics 10
 - therapeutic modulation 16
 - therapeutics 18
 - systems 9
 - therapeutic tools 21
 - thromboresistive surfaces 17
 - thrombosis 64
 - tissue engineering (TE) 15, 17, 22, 319
 - tissue mechanics across length scales 210, 211
 - tissue plasminogen activator (tPA) 61
 - titanium dioxide 336, 337
 - nanoparticles 332
 - titanium load-bearing implants 306
 - toll-like receptor (TLR7) agonist imiquimod 343
 - top-down technology 301
 - toxicity 127
 - trans-cis* azobenzene isomerization 76
 - transcutaneous immune modulation 338
 - transfersome 330
 - transformed cells, exhibiting increased spreading under low oxygen 196

- transfusions 90
 transplantation medicine, problem of 33
 tumor-associated cancer stem cells (CSCs) 142
 tumor targeting 343
 two-dimensional scanning small-angle X-ray scattering 248
 tyrosine kinase Src 367
- u**
- ultraviolet radiation (UVR) 337
 unilamellar liposome 76
 unmet needs, in cardiology 54, 55
 unsaturated phospholipids 75
 urethra compression model 319
 urethral compression, physical parameters 319
 urethral tissue, mechanical properties of 318
 urinary continence, physics of 318, 319
 urinary incontinence 323, 324
 – causes of 317
 – etiology 316
 – identification 317
 – risk factors 317
 – symptoms 315
 – tissue engineering/sling material for sphincter regeneration 319, 320
 – urinary in-/continence assessment 316–318
 urodynamic testing 318
- v**
- van der Waals interaction 73
 vascular cell adhesion molecule (VCAM-1) 60
 vascular endothelial growth factor (VEGF) pathway 227
- vasodilators 3, 59
 vasorelaxation 59
 vesicle release, stimulus for 85, 86
 – C5b–C9 complex 85
 virosomes 331
- w**
- wall shear stresses (WSS) 60
 – in coronary arteries 61
 – critically constricted arteries 61
 – in critically constricted coronary arteries 61
 – critically constricted human coronary artery 61
 – in healthy vessels 61
 – sensitive liposomes using artificial Pad-PC-Pad 61
 wide-angle X-ray scattering (WAXS) 244, 245, 252
 – patterns of enamel and dentin 254
 WSS. *see* wall shear stresses (WSS)
- x**
- xenografts 33
 x-ray imaging techniques 243
 x-ray scattering 4, 244
 – experimental setup for 246
- y**
- Young's modulus 327
- z**
- zinc oxide 332, 336, 337
 – nanoparticles 380

